慢性閉塞性肺疾患治療市場：薬剤タイプ、製品タイプ、検査、用途別-2025-2030年世界予測

慢性閉塞性肺疾患治療市場は、2023年に775億米ドルと評価され、2024年には833億9,000万米ドルに達すると予測され、CAGR 7.69％で成長し、2030年には1,302億4,000万米ドルに達すると予測されています。

慢性閉塞性肺疾患（COPD）治療には、症状の管理、QOLの改善、疾患の進行抑制を目的とした様々な治療アプローチが含まれます。効果的なCOPD治療の必要性は、この衰弱性疾患の有病率の上昇から生じており、その主な原因は大気汚染の増加、喫煙率の上昇、高齢化です。これらの治療は、息苦しさを軽減し、慢性増悪を予防し、身体活動を強化することに応用されます。最終用途の範囲には、病院、診療所、在宅介護の現場が含まれ、気管支拡張薬、コルチコステロイド、酸素療法、肺リハビリテーションなどの選択肢が利用されます。COPD治療市場の主な成長要因としては、吸入器技術の進歩、炎症経路を標的とする新規生物製剤のイントロダクション、患者意識の高まりなどが挙げられます。遠隔モニタリングや遠隔医療プラットフォームのようなデジタルヘルス統合は、個別化された治療計画やアドヒアランスサポートを提供するものであり、市場機会はそこにあります。しかし、高い薬剤開発コスト、厳しい規制の枠組み、長期の薬物療法による副作用など、大きな課題も残されています。さらに、初期のCOPDでは誤診が多く、治療が不十分であることも市場拡大の妨げとなっています。イノベーションの道は、早期診断のための生物学的マーカー、全身的副作用を軽減する次世代ドラッグデリバリーシステム、肺組織の修復を目的とした細胞療法のような再生医療アプローチに焦点を当てるべきです。市場は本質的にダイナミックであり、ジェネリック医薬品の着実な参入や、既存製薬企業と新興バイオテクノロジー企業との競争を特徴としています。最適な事業成長のためには、企業は研究協力を優先し、個別化治療や低侵襲治療におけるアンメットニーズに対応する患者中心のソリューションに投資すべきです。進化する患者の嗜好や治療法の進歩に合わせた機敏なアプローチを採用することで、市場での地位を高め、持続的な成長を促すことができます。

市場力学：急速に進化する慢性閉塞性肺疾患治療市場の主要市場インサイトを公開

慢性閉塞性肺疾患治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響についてより明確に理解することができます。

• 市場促進要因
  • 老人人口の増加と不健康なライフスタイルの増加
  • 喘息および慢性閉塞性肺疾患（COPD）の患者数の増加
  • デジタル喘息ケア機器に対する消費者の意識の高まり
• 市場抑制要因
  • 政府による厳しい吸入器承認規制
• 市場機会
  • 喘息治療器具の急速な技術進歩および新製品の発売
  • 在宅ケア治療機器への高い需要
• 市場の課題
  • 吸入器に対する価格圧力と特許切れの増加

ポーターの5つの力：慢性閉塞性肺疾患治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：慢性閉塞性肺疾患治療市場における外部からの影響の把握

外部マクロ環境要因は、慢性閉塞性肺疾患治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析慢性閉塞性肺疾患治療市場における競合情勢の把握

慢性閉塞性肺疾患治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス慢性閉塞性肺疾患治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、慢性閉塞性肺疾患治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨慢性閉塞性肺疾患治療市場における成功への道筋を描く

慢性閉塞性肺疾患治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢者人口の増加と不健康なライフスタイルの増加
    • 喘息と慢性閉塞性肺疾患（COPD）のジオイング数
    • デジタル喘息ケア機器に対する消費者の意識向上
  • 抑制要因
    • 政府による吸入器の承認に対する厳しい規制
  • 機会
    • 喘息治療機器の急速な技術進歩と新製品の発売
    • 在宅ケア治療機器の需要が高い
  • 課題
    • 吸入器の価格圧力の高まりと特許切れ
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 慢性閉塞性肺疾患治療市場薬の種類別

• 抗生物質
• 抗コリン剤
• ベータ2作動薬
• メチルキサンチン
• 経口コルチコステロイド
• ホスホジエステラーゼ4阻害剤

第7章 慢性閉塞性肺疾患治療市場：製品別

• 吸入器
• ネブライザー

第8章 慢性閉塞性肺疾患治療市場テスト別

• 動脈血ガス検査
• 胸部X線検査
• CTスキャン
• 遺伝子検査
• 肺機能検査

第9章 慢性閉塞性肺疾患治療市場：用途別

• 慢性気管支炎
• 肺気腫
• 難治性喘息

第10章 南北アメリカの慢性閉塞性肺疾患治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の慢性閉塞性肺疾患治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの慢性閉塞性肺疾患治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Adamis Pharmaceuticals Corporation
• Almirall, S.A.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Chiesi Farmaceutici S.p.A.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Novartis AG
• Orion Oyj
• Sunovion Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA2-AGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METHYLXANTHINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ORAL CORTICOSTEROID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ARTERIAL BLOOD GAS TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CHEST X-RAY TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GENETIC TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY LUNG FUNCTIONAL TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY EMPHYSEMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REFRACTORY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 41. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 43. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 63. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 65. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 67. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 68. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 69. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 136. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 138. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 152. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 153. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 154. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 156. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 157. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 158. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 195. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 196. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Chronic Obstructive Pulmonary Disease Treatment Market was valued at USD 77.50 billion in 2023, expected to reach USD 83.39 billion in 2024, and is projected to grow at a CAGR of 7.69%, to USD 130.24 billion by 2030.

Chronic Obstructive Pulmonary Disease (COPD) treatment encompasses an array of therapeutic approaches aimed at managing symptoms, improving quality of life, and slowing disease progression. The necessity for effective COPD treatments arises from the rising prevalence of this debilitating disease, largely driven by increased air pollution, smoking rates, and an aging population. These treatments find application in reducing breathlessness, preventing chronic exacerbations, and enhancing physical activity. The end-use scope includes hospitals, clinics, and home care settings, where options such as bronchodilators, corticosteroids, oxygen therapy, and pulmonary rehabilitation are utilized. Key growth influencers in the COPD treatment market include advancements in inhaler technologies, the introduction of novel biologics targeting inflammatory pathways, and increasing patient awareness. Market opportunities lie within the digital health integration-like remote monitoring and telemedicine platforms-offering personalized treatment plans and adherence support. However, substantial challenges remain, such as high drug development costs, stringent regulatory frameworks, and the adverse side effects of long-term pharmacotherapy. Additionally, the frequent misdiagnosis and under-treatment in early-stage COPD hinder market expansion. Innovation avenues should focus on biological markers for early diagnosis, next-generation drug delivery systems reducing systemic side effects, and regenerative medicine approaches like cellular therapies aimed at lung tissue restoration. The market is inherently dynamic, characterized by a steady entry of generic products and the competition between established pharmaceutical players and emerging biotechnology firms. For optimal business growth, companies should prioritize research collaborations and invest in patient-centric solutions addressing unmet needs in personalized and minimally invasive therapies. Embracing an agile approach that aligns with evolving patient preferences and therapeutic advancements will enhance market position and drive sustained growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chronic Obstructive Pulmonary Disease Treatment Market

The Chronic Obstructive Pulmonary Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increase in geriatric population and rise in unhealthy lifestyle
  • Geoing number of asthma and chronic obstructive pulmonary disease (COPD)
  • Increasing consumer awareness toward digital asthma care devices
• Market Restraints
  • Stringent regulations for inhaler approvals by the government
• Market Opportunities
  • Rapid technological advancements and new product launches in the asthma devices
  • High demand for home care therapeutic devices
• Market Challenges
  • Increased pricing pressures and patent expiries on inhalers

Porter's Five Forces: A Strategic Tool for Navigating the Chronic Obstructive Pulmonary Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chronic Obstructive Pulmonary Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chronic Obstructive Pulmonary Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chronic Obstructive Pulmonary Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chronic Obstructive Pulmonary Disease Treatment Market

A detailed market share analysis in the Chronic Obstructive Pulmonary Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chronic Obstructive Pulmonary Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chronic Obstructive Pulmonary Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chronic Obstructive Pulmonary Disease Treatment Market

A strategic analysis of the Chronic Obstructive Pulmonary Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chronic Obstructive Pulmonary Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adamis Pharmaceuticals Corporation, Almirall, S.A., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Orion Oyj, Sunovion Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Chronic Obstructive Pulmonary Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Antibiotic, Anticholinergic, Beta2-agonists, Methylxanthines, Oral Corticosteroid, and Phosphodiesterase-4 Inhibitors.
• Based on Product, market is studied across Inhalers and Nebulizers.
• Based on Test, market is studied across Arterial Blood Gas Test, Chest X-ray Test, CT scan, Genetic Test, and Lung Functional Test.
• Based on Application, market is studied across Chronic Bronchitis, Emphysema, and Refractory Asthma.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in geriatric population and rise in unhealthy lifestyle
    • 5.1.1.2. Geoing number of asthma and chronic obstructive pulmonary disease (COPD)
    • 5.1.1.3. Increasing consumer awareness toward digital asthma care devices
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent regulations for inhaler approvals by the government
  • 5.1.3. Opportunities
    • 5.1.3.1. Rapid technological advancements and new product launches in the asthma devices
    • 5.1.3.2. High demand for home care therapeutic devices
  • 5.1.4. Challenges
    • 5.1.4.1. Increased pricing pressures and patent expiries on inhalers
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Chronic Obstructive Pulmonary Disease Treatment Market, by Drug Type

• 6.1. Introduction
• 6.2. Antibiotic
• 6.3. Anticholinergic
• 6.4. Beta2-agonists
• 6.5. Methylxanthines
• 6.6. Oral Corticosteroid
• 6.7. Phosphodiesterase-4 Inhibitors

7. Chronic Obstructive Pulmonary Disease Treatment Market, by Product

• 7.1. Introduction
• 7.2. Inhalers
• 7.3. Nebulizers

8. Chronic Obstructive Pulmonary Disease Treatment Market, by Test

• 8.1. Introduction
• 8.2. Arterial Blood Gas Test
• 8.3. Chest X-ray Test
• 8.4. CT scan
• 8.5. Genetic Test
• 8.6. Lung Functional Test

9. Chronic Obstructive Pulmonary Disease Treatment Market, by Application

• 9.1. Introduction
• 9.2. Chronic Bronchitis
• 9.3. Emphysema
• 9.4. Refractory Asthma

10. Americas Chronic Obstructive Pulmonary Disease Treatment Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Adamis Pharmaceuticals Corporation
• 3. Almirall, S.A.
• 4. Astellas Pharma Inc.
• 5. AstraZeneca PLC
• 6. Bayer AG
• 7. Boehringer Ingelheim Pharmaceuticals, Inc.
• 8. Chiesi Farmaceutici S.p.A.
• 9. F. Hoffmann-La Roche Ltd.
• 10. GlaxoSmithKline Plc
• 11. Johnson & Johnson Services, Inc.
• 12. Merck & Co., Inc.
• 13. Novartis AG
• 14. Orion Oyj
• 15. Sunovion Pharmaceuticals Inc.
• 16. Teva Pharmaceutical Industries Ltd.